

18 May 2026

## Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 14 May 2026, an award of the Company's ordinary shares of \$0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP).

The AZPSP award was granted on 14 May 2021 as part of the award granted to Mr Soriot on 5 March 2021, and reflected the revised limits of the AZPSP, as approved by shareholders at the Company's 2021 Annual General Meeting. The award was subject to a combination of performance measures focused on scientific, commercial, financial and sustainability performance, assessed over a three-year performance period. On the third anniversary of grant the award was placed in a two-year holding period. The award vested at the end of that holding period. Application of the performance measures specified at the time of grant resulted in 88% of the AZPSP award vesting and the remaining unvested part lapsing.

Following the reinvestment of dividends accrued during performance and holding periods of the AZPSP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Soriot's beneficial interests in Ordinary Shares changed as detailed in the table below:

<b>PDMR</b>	<b>Ordinary Shares acquired under the AZPSP</b>
Pascal Soriot	18,359

For tax purposes, the fair market value of an Ordinary Share at vest of the AZPSP award was 13,766 pence, being the closing price on the London Stock Exchange on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Pascal Soriot
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	Ordinary Shares of US\$0.25 each in AstraZeneca PLC
	Identification code	GB0009895292

b)	Nature of the transaction	Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		0	18,359
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction	
e)	Date of the transaction	14 May 2026	
f)	Place of the transaction	Outside a trading venue	

### **AstraZeneca**

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit [astrazeneca.com](https://astrazeneca.com) and follow the Company on Social Media [@AstraZeneca](https://twitter.com/AstraZeneca).

### **Contacts**

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

**Matthew Bowden**  
**Company Secretary**  
**AstraZeneca PLC**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).